Cipher Pharmaceuticals Stock Net Asset
| CPHRF Stock | USD 10.35 0.04 0.38% |
Fundamental analysis of Cipher Pharmaceuticals allows traders to better anticipate movements in Cipher Pharmaceuticals' stock price by examining its financial health and performance throughout various phases of its business cycle.
Cipher |
Cipher Pharmaceuticals OTC Stock Net Asset Analysis
Cipher Pharmaceuticals' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current Cipher Pharmaceuticals Net Asset | 51.65 M |
Most of Cipher Pharmaceuticals' fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cipher Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
| Competition |
Based on the recorded statements, Cipher Pharmaceuticals has a Net Asset of 51.65 M. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The net asset for all United States stocks is notably lower than that of the firm.
Cipher Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cipher Pharmaceuticals' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Cipher Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Cipher Pharmaceuticals by comparing valuation metrics of similar companies.Cipher Pharmaceuticals is currently under evaluation in net asset category among its peers.
Cipher Fundamentals
| Return On Equity | 0.24 | |||
| Return On Asset | 0.15 | |||
| Profit Margin | 0.45 % | |||
| Operating Margin | 0.57 % | |||
| Current Valuation | 46.13 M | |||
| Shares Outstanding | 25.12 M | |||
| Shares Owned By Insiders | 44.12 % | |||
| Number Of Shares Shorted | 11.43 K | |||
| Price To Earning | 15.54 X | |||
| Price To Book | 1.63 X | |||
| Price To Sales | 3.28 X | |||
| Revenue | 21.94 M | |||
| Gross Profit | 18.26 M | |||
| EBITDA | 11.85 M | |||
| Net Income | 7.76 M | |||
| Cash And Equivalents | 24.19 M | |||
| Cash Per Share | 0.96 X | |||
| Total Debt | 507 K | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 2.51 X | |||
| Book Value Per Share | 1.77 X | |||
| Cash Flow From Operations | 13.81 M | |||
| Short Ratio | 0.97 X | |||
| Earnings Per Share | 0.36 X | |||
| Target Price | 5.59 | |||
| Number Of Employees | 26 | |||
| Beta | 1.03 | |||
| Market Capitalization | 64.32 M | |||
| Total Asset | 51.65 M | |||
| Z Score | 75.6 | |||
| Net Asset | 51.65 M |
About Cipher Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Cipher Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cipher Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cipher Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| VOO | Vanguard SP 500 | |
| XLK | Technology Select Sector | |
| XLV | Health Care Select | |
| QQQ | Invesco QQQ Trust | |
| XLC | Communication Services Select |
Other Information on Investing in Cipher OTC Stock
Cipher Pharmaceuticals financial ratios help investors to determine whether Cipher OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Cipher with respect to the benefits of owning Cipher Pharmaceuticals security.